



FDA Approval Decisions Report March-May 2008

Jeremy Zhou
Senior Analyst
415-782-0454, x158
jzhou@reveredata.com

Daniel Grundig
Analyst
415-782-0454, x176
dgrundig@reveredata.com

Overview

For investors in pharmaceutical and biotech companies, rigorous monitoring of drug pipelines is essential. No milestone is more influential than the FDA approval decision date, frequently called the PDUFA date (from Prescription Drug User Fee Act).

This Revere Report features **companies with expected FDA approval decision dates in the next three months**. To provide further insights into **each drug candidate's likelihood of approval and competitive landscape**, the FDA Approval Decisions Report includes **key data based on Revere's patented classification system and proprietary pipeline database** - specifically, whether each drug candidate:

- utilizes a mechanism of action already approved by the FDA in other drugs
- faces two or fewer alternative drugs with the same mechanism of action for the same indication
- would be the first or second FDA approved drug for the company

Contents

- Recent Approval Results/Updates
- Expected PDUFA Dates in the Next Three Months
- Price and Financial Info

Copyright 2007 by Revere Data, LLC. All rights reserved.

Notes:

1. Some expected PDUFA (Prescription Drug User Fee Act) dates are Revere estimates based on NDA (New Drug Approval) submission dates. Companies are not obligated to disclose NDA submission dates or PDUFA dates, and the FDA may change its approval decision date without prior notice.
2. Drugs developed by private firms or by companies not traded publicly in the U.S. are excluded from this analysis.

Disclaimer:

Revere Data is an independent provider of investment research and information and does not offer broker / dealer, money management, hedge fund management, investment advisory, or investment banking services.

The information contained in this report is based on a limited analysis of qualitative, statistical, and financial data and should not be interpreted as recommendations based on a complete investment evaluation. The information is based on sources that Revere Data believes to be reliable, but no representation, express or implied, is made with respect to the accuracy, completeness, reliability, or timeliness. The information is subject to change without notice, and Revere Data does not accept responsibility to update it.

Revere Data does not accept responsibility or liability for any direct, indirect, special, consequential, or other losses or damages of any kind whatsoever arising out of access to, or use of, this report or any information contained in it.

For more information on Revere's independent research data and investment analytics, please contact us as follows:

Revere Data, LLC | 60 East 42nd St. Suite 716 | New York, NY 110165
866.REVERE9 (866.738.3739) | sales@reveredata.com | www.reveredata.com

Recent Approval Results/Updates

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Previous Expected PDUFA Date	Approval results/update
Axcan Pharma Inc. (USA) (AXCA) / Ultrase (Pancrelipase)/Ultrase MT (Pancrelipase)				
	Chronic Pancreatitis, Exocrine Pancreatic Insufficiency, Pancreatic Deficiency Related To Cystic Fibrosis (CF)	Enzyme Replacement Therapy	02/01/2008	Result Pending
AstraZeneca plc (ADR) (AZN) / Humira (Adalimumab)				
	Moderate To Severe Chronic Plaque Psoriasis	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	02/01/2008	Approved 01/18/2008
Abbott Laboratories (ABT) / Humira (Adalimumab)				
	Moderate To Severe Chronic Plaque Psoriasis	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	02/01/2008	Approved 01/18/2008
Wyeth (WYE) / Pristiq (Desvenlafaxine Succinate)				
	Major Depressive Disorder	Selective Norepinephrine Reuptake Inhibitors (SNRI)	Feb 2008	Approved 02/29/2008
GlaxoSmithKline plc (ADR) (GSK) / Infanrix-IPV/Kinrix (Diphtheria, Tetanus, Acellular Pertussis-Inactivated Polio Virus Vaccine (DTaP-IPV))				
	Diphtheria, Tetanus, Acellular Pertussis And Polio Vaccine	Diphtheria/Tetanus/Acellular Pertussis (DTaP)	Feb 2008	Result Pending
GlaxoSmithKline plc (ADR) (GSK) / Entereg (Alvimopan)				
	Post-Operative Ileus (POI)	Opioid Receptor Antagonists	<u>02/08/2008</u>	Rescheduled to 05/09/2008
Adolor Corporation (ADLR) / Entereg (Alvimopan)				
	Post-Operative Ileus (POI)	Opioid Receptor Antagonists	<u>02/08/2008</u>	Rescheduled to 05/09/2008
sanofi-aventis (ADR) (SNY) / Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)				
	Vaginal And Vulvar Cancer Vaccine	Papillomavirus, Papillomavirus Vaccines	02/15/2008	Result Pending
Merck & Co., Inc. (MRK) / Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)				
	Vaginal And Vulvar Cancer Vaccine	Papillomavirus, Papillomavirus Vaccines	02/15/2008	Result Pending
Abbott Laboratories (ABT) / KOS Pharmaceuticals Simcor (Niacin/Simvastatin)				
	Hypercholesterolemia, Dyslipidemia	Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)	02/20/2008	Approved 02/15/2008
Roche Holding Ltd. (ADR) (RHHBY) / Avastin (Bevacizumab)				
	First-Line Treatment Of HER2-Negative Metastatic Breast Cancer In Combination With Paclitaxel	Monoclonal Antibodies	<u>02/22/2008</u>	Approved 02/22/2008
Genentech, Inc. (DNA) / Avastin (Bevacizumab)				
	First-Line Treatment Of HER2-Negative Metastatic Breast Cancer In Combination With Paclitaxel	Monoclonal Antibodies	<u>02/22/2008</u>	Approved 02/22/2008
Solvay S.A. (ADR) (SVYSY) / Solvay Pharmaceuticals Luvox CR (Fluvoxamine Controlled Release)				
	Obsessive Compulsive Disorder (OCD) And Social Anxiety Disorder (SAD)	Selective Serotonin Reuptake Inhibitors (SSRI)	<u>02/29/2008</u>	Approved 02/28/2008
Jazz Pharmaceuticals, Inc. (JAZZ) / Luvox CR (Fluvoxamine Controlled Release)				
	Obsessive Compulsive Disorder (OCD) And Social Anxiety Disorder (SAD)	Selective Serotonin Reuptake Inhibitors (SSRI)	<u>02/29/2008</u>	Approved 02/28/2008
Regeneron Pharmaceuticals, Inc. (REGN) / Arcalyst (Riloncept)				

Company (Symbol) / Drug Candidate			
Cryopyrin-Associated Periodic Syndrome (CAPS) In Adults And Children 12 And Older	Interleukin-1 Receptor Antagonists (IL-1 Antagonists)	<u>02/29/2008</u>	Approved 02/27/2008
Eli Lilly & Co. (LLY) / Zyprexa Adhera Long-Acting Injection (Intramuscular Olanzapine Pamoate Depot)			
Once Every 2 To 4 Weeks Long Acting Treatment Of Schizophrenia	Monoaminergic Antagonists	Mar 2008	Non-Approvable Letter Received 02/28/2008
AstraZeneca plc (ADR) (AZN) / Humira (Adalimumab)			
Juvenile Rheumatoid Arthritis (JRA)	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	03/07/2008	Approved 02/22/2008
Abbott Laboratories (ABT) / Humira (Adalimumab)			
Juvenile Rheumatoid Arthritis (JRA)	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	03/07/2008	Approved 02/22/2008
Bristol Myers Squibb Co. (BMY) / Abilify (Aripiprazole)/Abilify Discmelt (Aripiprazole Orally Disintegrating Tablet)			
Bipolar I Disorder, Manic Or Mixed Episode With Or Without Psychotic Features In Pediatric Patients Aged 10-17	Serotonin/Dopamine Receptor Partial Agonists	03/14/2008	Approved 02/28/2008

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases.

Expected PDUFA Dates in the Next Three Months

March Drug Candidates

Companies

Cephalon, Inc. (CEPH)
 CV Therapeutics, Inc. (CVTX)
 Eisai Co., Ltd (ADR) (ESALY)
 Genta Incorporated (GNTA)
 Johnson & Johnson (JNJ)
 QLT Inc. (USA) (QLTI)
 Spectrum Pharmaceuticals, Inc. (SPPI)

Sectors

 Biopharmaceuticals
 Dermatology
 Digestive System
 Infectious Diseases
 Oncology
 Medical Devices
 Cardiology

Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Eisai Co., Ltd (ADR) (ESALY) / MGi Pharma Aloxi (Palonosetron)						
	Postoperative Nausea And Vomiting	Serotonin Receptor Antagonists	<u>03/04/2008</u>	Yes	No Multiple Drugs	No
Spectrum Pharmaceuticals, Inc. (SPPI) / ISO-vorin (Levofolinic Acid)						
	Osteosarcoma (Bone Cancer)	Folic Acid Derivatives	<u>03/07/2008</u>	Yes	Yes Only Candidate with This PMOA for This Indication	Yes
Genta Incorporated (GNTA) / Genasense (Oblimersen Sodium)						
	Chronic Lymphocytic Leukemia (CLL) In Combination With Fludarabine and Cyclophosphamide	Antisense Agents	03/14/2008	Yes	Yes Only Candidate with This PMOA for This Indication	Yes
CV Therapeutics, Inc. (CVTX) / Regadenoson						
	Diagnostic Cardiac Stress Test Used To Increase Blood Flow In Patients Undergoing Cardiac Perfusion Imaging Studies	Stress/Exercise Test	03/14/2008	No	Yes Binodenoson / (KG)	Yes
Johnson & Johnson (JNJ) / Ceftobiprole						
	Complicated Skin And Skin Structure Infections (cSSSI), Including Those Caused By Methicillin-Resistant Staphylococcus aureus (MRSA)	Cephalosporin Derivatives	<u>03/18/2008</u>	Yes	Yes Only Candidate with This PMOA for This Indication	No
Cephalon, Inc. (CEPH) / Treanda (Bendamustine Hydrochloride)						
	Chronic Lymphocytic Leukemia (CLL)	Nitrogen Mustard Type	03/21/2008	Yes	Yes Cytosan/Lyophilized Cytosan (Cyclophosphamide) / (BMY)	No
QLT Inc. (USA) (QLTI) / ACZONE Gel (Dapsone Topical Gel)						
	Treatment Of Moderate To Severe Acne Vulgaris Without Prior Blood Monitoring And Screening Of G6PD	Sulfonamides	03/28/2008	Yes	Yes Only Candidate with This PMOA for This Indication	No

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? 1st/2nd Drug -- 1st or 2nd FDA Approved Drug of the Company?

April Drug Candidates

Companies

Alcon, Inc. (ACL)
 AVANT Immunotherapeutics, Inc. (AVAN)
 Biovail Corporation (USA) (BVF)
 Bristol Myers Squibb Co. (BMY)
GlaxoSmithKline plc (ADR) (GSK) [2]
 Johnson & Johnson (JNJ)
Merck & Co., Inc. (MRK) [2]
 Neurochem Inc. (USA) (NRMX)
 Novo Nordisk A/S (ADR) (NVO)
 POZEN Inc. (POZN)
 Progenics Pharmaceuticals, Inc. (PGNX)
Schering-Plough Corporation (SGP) [2]
 Sciele Pharma Inc. (SCRX)
 Shire plc (ADR) (SHPGY)
 Solvay S.A. (ADR) (SVYSY)
 Sucampo Pharmaceuticals, Inc. (SCMP)
 Warner Chilcott Ltd. (WCRX)
 Wyeth (WYE)

Sectors

- Biopharmaceuticals
 - ◆ Allergies
 - ◆ Dermatology
 - ◆ Digestive System
 - ◆ Endocrinology/Metabolism
 - ◆ Hematology
 - ◆ Immunology
 - ◆ Infectious Diseases
 - ◆ Musculoskeletal System
 - ◆ Neurology
 - ◆ Oncology
 - ◆ Ophthalmology

Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Alcon, Inc. (ACL) / Tobradex ST (Tobramycin/Dexamethasone)	Steroid-Responsive Inflammatory Ocular Conditions Associated With Bacterial Infections	Aminoglycosides/Steroidal Anti-Inflammatory Drugs (SAID), Antibacterial Agents/Steroidal Anti-Inflammatory Drugs (SAID)	Apr 2008	Yes	No Multiple Drugs	No
Neurochem Inc. (USA) (NRMX) / Kiacta (Eprodisate)/Formerly Fibrillex	Amyloid A Amyloidosis (AA Amyloidosis)	Glycosaminoglycan (GAG) Mimetic Agents	<u>04/02/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	Yes
Johnson & Johnson (JNJ) / Doribax (Doripenem)	Nosocomial Pneumonia	Carbapenems	04/04/2008	Yes	Yes Invanz (Ertapenem Sodium) / (MRK)	No
Bristol Myers Squibb Co. (BMY) / Orencia (Abatacept)	Juvenile Rheumatoid Arthritis (JRA) Who Have Had An Inadequate Response To One Or More DMARDs	Immunosuppressants	04/07/2008	Yes	Yes Only Candidate with This PMOA for This Indication	No
Solvay S.A. (ADR) (SVYSY) / Unimed Pharmaceuticals Androgel (Testosterone Gel)	Primary Or Secondary Hypogonadism In Male Adolescents Ages 13-17 Years Old, Constitutional Delay In Growth And Puberty (CDGP) In Male Adolescents	Androgens	04/14/2008	Yes	Yes Only Candidate with This PMOA for This Indication	No
POZEN Inc. (POZN) / Treximet (Naproxen/Sumatriptan)	First-Line Therapy For Acute Migraine Attacks	Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Selective Serotonin Receptor Agonists	<u>04/15/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	Yes
GlaxoSmithKline plc (ADR) (GSK) / Treximet (Naproxen/Sumatriptan)						

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
	First-Line Therapy For Migraine Headaches	Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Selective Serotonin Receptor Agonists	04/15/2008	No	Yes Only Candidate with This PMOA for This Indication	No
Sciele Pharma Inc. (SCRX) / PrandiMet (Repaglinide/Metformin Fixed Combo)						
	Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes	Biguanides/Insulin Stimulating Agents	04/15/2008	Yes	Yes Glucovance (Metformin/Glyburide) / (BMY) Metaglip (Metformin/Glipizide) / (BMY)	No
Novo Nordisk A/S (ADR) (NVO) / PrandiMet (Repaglinide/Metformin Fixed Combo)						
	Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes	Biguanides/Insulin Stimulating Agents	04/15/2008	Yes	Yes Glucovance (Metformin/Glyburide) / (BMY) Metaglip (Metformin/Glipizide) / (BMY)	No
Biovail Corporation (USA) (BVF) / BVF-033 (Once-Daily Bupropion Salt)						
	Depression	Serotonin/Norepinephrine Reuptake Inhibitors	04/23/2008	Yes	Yes Tyco Healthcare Tofranil (Imipramine Hydrochloride) / (COV) Cymbalta (Duloxetine Hydrochloride) / (LLY)	No
GlaxoSmithKline plc (ADR) (GSK) / Rotarix (Rotavirus Vaccine)						
	Rotavirus Gastroenteritis Vaccine	Rotavirus	04/25/2008	Yes	Yes Rotateq / (MRK)	No
AVANT Immunotherapeutics, Inc. (AVAN) / Rotarix (Rotavirus Vaccine)						
	Rotavirus Gastroenteritis Vaccine	Rotavirus	04/25/2008	Yes	Yes Rotateq / (MRK)	Yes
Schering-Plough Corporation (SGP) / PEG-Intron A (Peginterferon Alfa-2b)						
	Malignant Melanoma (Skin Cancer)	Interferons	04/28/2008	Yes	Yes Only Candidate with This PMOA for This Indication	No
Schering-Plough Corporation (SGP) / Claritin (Loratadine)/Singulair (Montelukast)						
	Seasonal Allergic Rhinitis (SAR)	Antihistamines/Leukotriene Receptor Antagonists	04/28/2008	No	Yes Only Candidate with This PMOA for This Indication	No
Merck & Co., Inc. (MRK) / Claritin (Loratadine)/Singulair (Montelukast)						
	Seasonal Allergic Rhinitis (SAR)	Antihistamines/Leukotriene Receptor Antagonists	04/28/2008	No	Yes Only Candidate with This PMOA for This Indication	No
Shire plc (ADR) (SHPGY) / Vyvanse (Lisdexamfetamine Dimesylate)/Formerly NRP104						
	Attention Deficit Hyperactivity Disorder (ADHD) In Adult Patients 18-55 Years Of Age	Sympathomimetic Agents	04/28/2008	Yes	Yes Dexedrine (Dextroamphetamine Sulfate) / (GSK)	No
Warner Chilcott Ltd. (WCRX) / Taclonex Scalp Gel (Calcipotriene/Betamethasone Dipropionate)						
	Scalp Psoriasis Vulgaris	Vitamin D Analogs/Steroidal Anti-Inflammatory Drugs (SAID)	04/29/2008	Yes	Yes Only Candidate with This PMOA for This Indication	No
Sucampo Pharmaceuticals, Inc. (SCMP) / Amitiza (Lubiprostone)						
	Irritable Bowel Syndrome (IBS) With Constipation	Chloride Channel Activators	04/29/2008	No	Yes Only Candidate with This PMOA for This Indication	Yes
Merck & Co., Inc. (MRK) / Cordaptive (ER Niacin/Laropiprant)/Formerly MK-0524A						

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
	Adjunctive Therapy To Diet For The Treatment Of Elevated LDL Cholesterol, Low HDL Cholesterol And Elevated Triglycerides Levels	Free Fatty Acid Inhibitors/Prostaglandin Inhibitors	04/29/2008	No	Yes Only Candidate with This PMOA for This Indication	No
Wyeth (WYE) / MNTX (Subcutaneous Methylnaltrexone)						
	Opioid-Induced Constipation (OIC) In Patients Receiving Palliative Care	Opioid Receptor Antagonists	<u>04/30/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	No
Progenics Pharmaceuticals, Inc. (PGNX) / MNTX (Subcutaneous Methylnaltrexone)						
	Opioid-Induced Constipation (OIC) In Patients Receiving Palliative Care	Opioid Receptor Antagonists	<u>04/30/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	Yes

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1st/2nd Drug** -- 1st or 2nd FDA Approved Drug of the Company?

May Drug Candidates

Companies

Abbott Laboratories (ABT)
Adolor Corporation (ADLR)
Akorn, Inc. (AKRX)
Discovery Laboratories, Inc. (DSCO)
GlaxoSmithKline plc (ADR) (GSK)
Ligand Pharmaceuticals Inc. (LGND)
Salix Pharmaceuticals, Ltd. (SLXP)
Schering-Plough Corporation (SGP)
The Medicines Company (MDCO)
Wyeth (WYE)

Sectors

- Biopharmaceuticals
 - ◆ Digestive System
 - ◆ Immunology
 - ◆ Infectious Diseases
 - ◆ Musculoskeletal System
 - ◆ Pain Management
 - ◆ Respiratory System
 - ◆ Surgery

Notes:

1. Some drug candidates are filed jointly by two companies.
2. Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Wyeth (WYE) / Viviant (Bazedoxifene)						
	Treatment Of Postmenopausal Osteoporosis	Selective Estrogen Receptor Modulators (SERM)	May 2008	Yes	No Multiple Drugs	No
Ligand Pharmaceuticals Inc. (LGND) / Viviant (Bazedoxifene)						
	Treatment Of Postmenopausal Osteoporosis	Selective Estrogen Receptor Modulators (SERM)	May 2008	Yes	No Multiple Drugs	Yes
Discovery Laboratories, Inc. (DSCO) / Surfaxin (Lucinactant)						
	Prevention Of Respiratory Distress Syndrome In Premature Infants (RDS)	Surfactants	<u>05/01/2008</u>	Yes	No Multiple Drugs	Yes
Schering-Plough Corporation (SGP) / Organon Sugammadex Sodium Injection						
	Reversal Of General Anesthesia Effects Of Certain Muscle Relaxants Such As Rocuronium Bromide Or Vecuronium Bromide	Selective Relaxant Binding Agents	05/02/2008	No	Yes Only Candidate with This PMOA for This Indication	No
The Medicines Company (MDCO) / Cleviprex (Clevipidine)						
	Short-Term Hypertension Associated With Cardiac Surgery	Calcium Channel Blocking Agents	05/02/2008	Yes	Yes Only Candidate with This PMOA for This Indication	Yes
Akorn, Inc. (AKRX) / Akten Ophthalmic Gel (Ocular Anesthetic Formulation)						
	Ocular Anesthesia	Analgesics/Opioids	<u>05/02/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	No
GlaxoSmithKline plc (ADR) (GSK) / Entereg (Alvimopan)						
	Post-Operative Ileus (POI)	Opioid Receptor Antagonists	<u>05/09/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	No
Adolor Corporation (ADLR) / Entereg (Alvimopan)						
	Post-Operative Ileus (POI)	Opioid Receptor Antagonists	<u>05/09/2008</u>	No	Yes Only Candidate with This PMOA for This Indication	Yes
Salix Pharmaceuticals, Ltd. (SLXP) / Colazal Tablet (Balsalazide Disodium)						
	Mild To Moderate Ulcerative Colitis	Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors	<u>05/16/2008</u>	Yes	No Multiple Drugs	No
Abbott Laboratories (ABT) / Kaletra (Lopinavir/Ritonavir)						

Company (Symbol) / Drug Candidate	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Tablet Formulation For Treatment Of Pediatric HIV/AIDS	Protease Inhibitors	05/19/2008	Yes	Yes Only Candidate with This PMOA for This Indication	No

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1st/2nd Drug** -- 1st or 2nd FDA Approved Drug of the Company?

Price and Financial Info

March 2008

Data as of 03/03/2008

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Cephalon, Inc.	CEPH	61.81	4,144.453	2,342,364	536.57	95.31	826.3	-10.30%	0.64%
CV Therapeutics, Inc.	CVTX	5.85	349.046	1,313,474	n/a	0	174.2	-52.90%	-41.96%
Eisai Co., Ltd (ADR)	ESALY	35.80	10,173.021	5,683	2.41	3.5	1,397.5	-29.32%	-18.38%
Genta Incorporated	GNTA	0.46	13.994	352,173	3.19	3.17	15.5	-84.42%	-73.48%
Johnson & Johnson	JNJ	62.00	175,621.390	10,918,388	12.07	22.02	9,315.0	0.08%	11.02%
QLT Inc. (USA)	QLTI	2.90	216.399	574,578	1.73	78.47	126.7	-65.06%	-54.12%
Spectrum Pharmaceuticals, Inc.	SPPI	2.54	79.301	123,869	1.34	0	65.8	-53.31%	-42.37%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,

April 2008

Data as of 03/03/2008

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Alcon, Inc.	ACL	138.17	41,161.908	445,217	15.48	53.47	2,804.1	12.58%	23.52%
AVANT Immunotherapeutics, Inc.	AVAN	0.70	52.013	133,141	n/a	0	15.7	-49.56%	-38.62%
Biovail Corporation (USA)	BVF	14.21	2,288.147	767,724	3.67	0	416.5	-30.68%	-19.74%
Bristol Myers Squibb Co.	BMJ	22.25	44,051.280	13,000,562	10.40	59.38	2,225.0	-15.76%	-4.82%
GlaxoSmithKline plc (ADR)	GSK	44.16	121,018.843	2,839,734	11.76	69.63	6,235.8	-19.14%	-8.19%
Johnson & Johnson	JNJ	62.00	175,621.390	10,918,388	12.07	22.02	9,315.0	0.08%	11.02%
Merck & Co., Inc.	MRK	43.90	95,056.232	15,033,166	5.93	31.56	8,230.8	-0.66%	10.29%
Neurochem Inc. (USA)	NRMX	1.51	73.758	141,640	5.88	185.54	70.0	-89.49%	-78.55%
Novo Nordisk A/S (ADR)	NVO	68.68	42,653.213	210,520	6.68	4.24	1,494.8	61.32%	72.26%
POZEN Inc.	POZN	12.22	362.992	252,335	10.30	0	73.9	-17.93%	-6.99%
Progenics Pharmaceuticals, Inc.	PGNX	15.40	457.518	353,135	2.90	0	145.7	-39.15%	-28.21%
Schering-Plough Corporation	SGP	21.24	34,402.894	16,493,552	n/a	n/a	n/a	-7.85%	3.09%
Sciele Pharma Inc.	SCRX	20.80	741.489	665,913	85.90	76.47	188.3	-6.14%	4.81%
Shire plc (ADR)	SHPGY	57.99	10,824.535	1,500,729	n/a	92.33	762.5	-7.26%	3.68%
Solvay S.A. (ADR)	SVYSY	124.55	10,549.526	367	n/a	n/a	n/a	-12.60%	-1.65%
Sucampo Pharmaceuticals, Inc.	SCMP	10.70	446.506	35,464	5.13	0	89.7	n/a	
Warner Chilcott Ltd.	WCRX	16.68	4,179.666	518,367	n/a	96.59	26.8	17.22%	28.16%
Wyeth	WYE	43.14	57,719.984	10,652,320	4.22	64.82	13,447.7	-11.63%	-0.69%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,

May 2008

Data as of 03/03/2008

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Abbott Laboratories	ABT	53.03	81,970.487	6,287,476	42.49	68.7	2,820.8	0.04%	10.98%
Adolor Corporation	ADLR	4.66	214.681	530,862	1.78	0	147.5	-29.74%	-18.80%
Akorn, Inc.	AKRX	6.11	536.107	326,116	9.96	0.5	10.3	4.62%	15.57%
Discovery Laboratories, Inc.	DSCO	2.03	175.778	749,047	4.53	41.56	53.0	-0.98%	9.97%
GlaxoSmithKline plc (ADR)	GSK	44.16	121,018.843	2,839,734	11.76	69.63	6,235.8	-19.14%	-8.19%

Ligand Pharmaceuticals Inc.	LGND	3.62	345.469	496,042	8.33	5.2	94.4	-67.99%	-57.05%
Salix Pharmaceuticals, Ltd.	SLXP	6.43	306.001	823,718	2.79	5.22	70.2	-52.12%	-41.18%
Schering-Plough Corporation	SGP	21.24	34,402.894	16,493,552	n/a	n/a	n/a	-7.85%	3.09%
The Medicines Company	MDCO	18.36	951.826	804,515	3.64	0	222.1	-28.59%	-17.65%
Wyeth	WYE	43.14	57,719.984	10,652,320	4.22	64.82	13,447.7	-11.63%	-0.69%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,